Brief: Alvotech, Dr. Reddy's Announce FDA Acceptance Of Biologic License Application
18/03/2025 13:50
March 18 (Reuters) - Alvotech SA ALVO.O: ALVOTECH AND DR. REDDY'S ANNOUNCE FDA ACCEPTANCE OF BIOLOGIC LICENSE APPLICATION FOR AVT03, A PROPOSED BIOSIMILAR TO PROLIA® AND XGEVA® Source text: ID:nGNERlH6z Further company coverage: ALVO.O (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Alvotech SA
See all newsBrief: CMS Announces Selection Of Drugs For Third Cycle Of The Medicare Drug Price Negotiation Program
Brief: Alvotech and Teva Secure U.S. Settlement Date For AVT06
India's Dr Reddy's rises after EU marketing authorisation for osteoporosis biosimilar
Brief: UK High Court Rules In Favor Of Alvotech Paving Way For AVT06, Biosimilar To Eylea
U.S. STOCKS ON THE MOVE-Cummins, EPAM Systems, Qualcomm